How Many Years Can a Healthy Lifestyle Add to Your Life? The Evidence on Diet, Exercise, Supplements & Anti-Aging Drugs (2026)
Short answer: A healthy lifestyle may add years to life—and potentially a decade or more in some populations—but there is no scientifically valid number that applies to everyone.
The strongest evidence suggests that the biggest gains come from a combination of not smoking, regular physical activity, a high-quality diet, maintaining a healthy body weight, and controlling major cardiovascular and metabolic risk factors.
One influential U.S. analysis estimated that people who followed five low-risk lifestyle factors at age 50 had a projected life expectancy about 14 years longer for women and 12 years longer for men than people following none of those factors. However, this was a prospective observational analysis combined with life-table modelling—not a randomized trial proving that each person will live exactly 12–14 years longer.
That distinction matters.
It is tempting to interpret longevity studies as if they were a prescription for an extra number of years: exercise gives three years, a Mediterranean diet gives four years, and a supplement gives another two. Human biology is not that simple.
The better-supported conclusion is that healthy behaviors can substantially reduce the probability of premature death and chronic disease. The size of the benefit depends on age, genetics, smoking history, metabolic health, existing disease, socioeconomic circumstances, environment and how consistently the behaviors are maintained.
What Does the Best Evidence Actually Show?
The most frequently cited analysis comes from researchers at Harvard T.H. Chan School of Public Health, using data from the Nurses' Health Study and Health Professionals Follow-up Study.
The researchers evaluated five lifestyle factors:
- Never smoking
- Healthy body mass index (18.5–24.9 kg/m² in the study)
- At least 30 minutes per day of moderate-to-vigorous physical activity
- A relatively high-quality diet
- Moderate alcohol consumption as defined by the study
Among people aged 50, the estimated life expectancy was approximately 43.1 additional years for women and 37.6 years for men among those with all five low-risk factors, compared with approximately 29.0 and 25.5 years, respectively, among those with none.
That corresponds to a projected difference of approximately 14.0 years for women and 12.2 years for men. The authors concluded that adopting a healthy lifestyle could substantially reduce premature mortality and prolong life expectancy.
Li et al., Circulation (2018), PubMed
Other Studies Point in the Same Direction
The Harvard analysis is not an isolated finding.
A Swedish prospective cohort study involving more than 64,000 adults found that four healthy behaviors—being a nonsmoker, regular physical activity, a healthier diet and lower-risk alcohol consumption—were each associated with lower all-cause mortality. People with all four healthy behaviors had an estimated survival-time advantage of approximately 4–5 years compared with those with none or one of the behaviors.
Larsson et al., Journal of Internal Medicine (2017), PubMed
A separate BMJ analysis looked at healthy years free from cancer, cardiovascular disease and type 2 diabetes. At age 50, women with four or five low-risk lifestyle factors had an estimated 34.4 years free of these diseases compared with 23.7 years among women with none. For men, the corresponding figures were 31.1 versus 23.5 years.
These findings support an important idea:
The potential benefit is not simply living longer. It may also mean spending more of those years without major chronic disease.
How Much Does Each Lifestyle Factor Matter?
1. Not Smoking Is Probably One of the Biggest Wins
Smoking is one of the strongest modifiable causes of premature death.
In the Harvard lifestyle analysis, never smoking was one of five factors associated with substantially lower mortality. The relationship is biologically plausible and supported by enormous amounts of epidemiological and clinical evidence.
Importantly, quitting smoking is beneficial even after years of smoking. The goal is therefore not perfection—it is eliminating tobacco exposure as early as possible.
Smoking cessation is likely to produce a much larger longevity benefit for a smoker than adding an exotic longevity supplement.
2. Exercise Has Strong Evidence
Physical activity is one of the most consistently supported longevity interventions.
The World Health Organization recommends that adults obtain approximately:
- 150–300 minutes per week of moderate-intensity aerobic activity, or
- 75–150 minutes per week of vigorous-intensity activity, or an equivalent combination.
WHO also recommends muscle-strengthening activities involving the major muscle groups on at least two days per week.
World Health Organization: Physical Activity
The evidence indicates that some activity is better than none, while additional activity can provide additional benefits, with diminishing returns at higher levels.
Importantly, exercise does not have to mean going to a gym. Walking, cycling, swimming, recreational sport, active transportation and physically demanding daily activities all contribute to total physical activity.
3. Diet Matters—but There Is No Single “Longevity Diet”
Healthy dietary patterns are consistently associated with lower risks of cardiovascular disease, diabetes and premature mortality.
Patterns resembling the Mediterranean and other minimally processed, plant-forward diets generally emphasize:
- Vegetables and fruits
- Legumes
- Whole grains
- Nuts and seeds
- Fish and other healthy protein sources
- Unsaturated fats such as olive oil
- Minimal ultra-processed foods
- Lower intake of processed meat and excess added sugars
The important point is not that one particular diet has magical anti-aging properties. Rather, healthier dietary patterns tend to improve several risk pathways simultaneously—including blood pressure, lipid metabolism, glucose regulation, body weight and cardiovascular risk.
Diet also interacts with other behaviors. A high-quality diet combined with regular physical activity and avoidance of tobacco is more meaningful than obsessing over a single “superfood.”
4. Healthy Weight Is Associated With Longer Life—but BMI Is Not the Whole Story
Maintaining a healthy body weight is associated with lower risk of several chronic diseases. However, body mass index is an imperfect measure of health.
BMI does not distinguish muscle from fat, does not show where body fat is distributed and does not capture metabolic health.
For longevity, it is more useful to consider the broader picture:
- Waist circumference and central adiposity
- Blood pressure
- Blood glucose and insulin resistance
- Blood lipids
- Physical fitness
- Muscle mass and strength
- Overall diet quality
The objective should therefore be metabolic and functional health, not simply achieving a particular number on a scale.
5. Alcohol Should Not Be Treated as a Longevity Supplement
Older observational studies sometimes found lower cardiovascular mortality among moderate drinkers. However, this evidence is difficult to interpret because of confounding and differences between drinkers and nondrinkers.
Consequently, it would be misleading to recommend starting alcohol consumption to extend life.
For people who do not drink, there is no evidence-based reason to begin drinking for longevity. For people who drink, lower consumption generally means lower exposure to alcohol-related harms.
What About Supplements?
This is where the evidence becomes much less impressive.
Supplements can be useful when they correct a deficiency, meet a specific nutritional requirement, or are prescribed for a particular medical indication. But the evidence that supplements substantially extend lifespan in otherwise healthy people is much weaker than the evidence for smoking cessation, physical activity and overall diet quality.
The U.S. Preventive Services Task Force reviewed randomized trials of vitamins, minerals and multivitamins for prevention of cardiovascular disease and cancer.
Its conclusions were notably cautious:
- There is insufficient evidence to determine whether multivitamins prevent cardiovascular disease or cancer.
- There is insufficient evidence for most individual vitamin or mineral supplements for these outcomes.
- Vitamin E is not recommended for preventing cardiovascular disease or cancer.
- Beta-carotene supplementation is not recommended for preventing cardiovascular disease or cancer and may increase lung cancer risk in people at increased risk, including smokers.
U.S. Preventive Services Task Force: Vitamin, Mineral, and Multivitamin Supplementation
The underlying systematic review included 84 studies involving approximately 739,803 participants. Overall, the authors found little or no benefit from vitamin and mineral supplementation for preventing cancer, cardiovascular disease and death, although there was some evidence of a small reduction in cancer incidence with multivitamins.
Can Vitamin D, Omega-3, Curcumin, NMN or Other Supplements Add Years?
There is currently no high-quality human evidence allowing us to say that a particular supplement reliably adds a specific number of years to human lifespan.
This distinction is especially important for compounds marketed as “anti-aging” interventions.
A supplement may:
- Improve a biomarker
- Correct a nutritional deficiency
- Improve a particular physiological function
- Reduce the risk of a specific condition in a defined population
- Show promising effects in animal or laboratory studies
None of those findings automatically demonstrate an increase in human lifespan.
For compounds such as NMN, NAD precursors, spermidine, urolithin A, curcumin and other proposed longevity agents, human research remains substantially less mature than the evidence for conventional lifestyle interventions.
It is therefore inappropriate to add hypothetical supplement benefits together and claim that a person can gain, for example, “20 extra years” by combining them.
Vitamin D is more complicated
Vitamin D is a good example of why we shouldn't lump all supplements together.
An older meta-analysis of 18 randomized trials involving 57,311 people found a modest reduction in all-cause mortality with vitamin D supplementation (RR 0.93, 95% CI 0.87–0.99). PubMed
But subsequent evidence has been considerably less definitive, and a later systematic review/meta-analysis included 80 randomized trials and more than 163,000 participants. PubMed
The bigger lesson is:
Correcting deficiency ≠ taking more vitamin D = living longer.
Someone who is deficient may benefit substantially from correction.
That doesn't establish that pushing vitamin D levels above normal produces additional longevity.
What About Anti-Aging Drugs?
If lifestyle interventions represent the foundation of longevity, the next frontier is geroscience: using drugs to target biological processes that contribute to aging itself.
This is potentially much more important than simply treating individual diseases. Instead of treating cancer, cardiovascular disease, diabetes and dementia separately, geroscience asks whether it is possible to slow underlying biological processes that increase the risk of many age-related diseases simultaneously.
Several drug classes are being investigated, including rapamycin and other mTOR inhibitors, metformin, senolytics and other compounds targeting cellular aging pathways.
Rapamycin: One of the Most Interesting Candidates
Rapamycin (sirolimus) is one of the best-known pharmacological candidates for targeting aging.
It inhibits the mTOR pathway, an important regulator of nutrient sensing, cell growth, protein synthesis and autophagy. In laboratory animals, inhibition of mTOR with rapamycin and related compounds can substantially extend lifespan, including when treatment begins relatively late in life.
That makes rapamycin particularly interesting from a geroscience perspective: the objective is not necessarily to treat one disease, but to influence a biological pathway involved in multiple aspects of aging.
However, animal results cannot simply be converted into human life-expectancy gains.
A 2024 systematic review of 19 human studies concluded that rapamycin or rapalogs improved some physiological parameters associated with aging, particularly in immune, cardiovascular and skin-related systems. However, significant benefits were not demonstrated across endocrine, muscular or neurological systems, and the long-term effects remain uncertain. Some studies also reported increased infections and adverse changes in blood lipids in people with age-related diseases.
Lee et al., Lancet Healthy Longevity (2024)
More recently, the 48-week PEARL randomized placebo-controlled trial investigated intermittent low-dose rapamycin in healthy adults. The study provides useful human safety and healthspan data, but it does not establish that rapamycin extends human lifespan.
A 2025 clinical evidence review reached a similar conclusion: although preclinical evidence is compelling, human studies have not established rapamycin or rapalogs as proven anti-aging therapies capable of delaying aging in healthy older adults.
Clinical evidence for off-label rapamycin in healthy adults (2025)
Metformin: An Anti-Aging Drug or a Diabetes Drug?
Metformin is another major geroscience candidate.
Unlike rapamycin, metformin is already widely used to treat type 2 diabetes. Researchers became interested in its potential longevity effects because observational studies have associated metformin use with lower rates of several age-related diseases and mortality in people with diabetes.
Potential mechanisms include effects on AMPK, insulin signaling, mitochondrial metabolism, inflammation, autophagy and nutrient-sensing pathways.
These mechanisms are biologically interesting, but they do not prove that metformin slows aging in healthy people.
The proposed Targeting Aging with Metformin (TAME) study was designed specifically to test whether metformin could delay the development of multiple age-related diseases rather than simply treating diabetes.
Development of Clinical Trials to Extend Healthy Lifespan — TAME
This distinction is crucial because evidence from people with diabetes cannot automatically be extrapolated to healthy adults taking metformin solely for longevity.
In fact, a long-term NIH-supported follow-up of the Diabetes Prevention Program Outcomes Study reported in 2026 found that lifestyle intervention significantly reduced the risk of developing multiple chronic conditions, whereas metformin did not produce a statistically significant reduction in multimorbidity compared with placebo.
Senolytics: Removing “Zombie” Cells
Senolytics are drugs designed to selectively eliminate senescent cells—cells that have stopped dividing normally but remain metabolically active and can release inflammatory signals.
Senescent cells accumulate with age and are thought to contribute to tissue dysfunction and chronic inflammation. In animal models, removing these cells has produced interesting effects on healthspan and age-related disease.
However, senolytics remain an early-stage area of human research.
The major unanswered questions include which senescent cells should be removed, which drugs can selectively eliminate them, what dosing schedule is appropriate, and whether eliminating senescent cells actually translates into longer human healthspan or lifespan.
Consequently, senolytics should currently be considered an experimental geroscience strategy, not an established longevity treatment.
Other Potential Anti-Aging Drugs
The field is considerably broader than rapamycin and metformin.
Researchers are investigating compounds that influence several biological pathways associated with aging, including:
- mTOR inhibitors: including rapamycin and rapalogs
- AMPK-modulating drugs: including metformin
- Senolytics: designed to remove senescent cells
- Autophagy-enhancing strategies: aimed at improving cellular recycling
- NAD-related interventions: targeting cellular energy and redox biology
- Anti-inflammatory approaches: targeting chronic low-grade inflammation
- Targeted metabolic interventions: designed to improve insulin sensitivity and nutrient sensing
Some of these interventions are supported mainly by laboratory and animal research, while others have entered human clinical trials.
The evidence therefore varies dramatically between compounds.
Why Anti-Aging Drugs Are Different From Supplements
There is an important conceptual difference between a nutritional supplement and a pharmacological gerotherapeutic.
A drug can be designed to deliberately manipulate a specific biological pathway at a pharmacologically active dose. That creates both greater potential efficacy and greater potential risk.
For example, mTOR inhibition can influence immune function, metabolism and cellular growth. That may be beneficial in some circumstances, but deliberately altering such a fundamental pathway can also produce adverse effects.
This is why “more pathway inhibition” does not necessarily mean “more longevity.”
Could Anti-Aging Drugs Eventually Add 5, 10 or 20 Years?
It is possible that future geroscience therapies could substantially increase healthy life expectancy, but there is currently no reliable human evidence supporting a specific number of additional years.
This is an important difference between what is biologically plausible and what has been demonstrated clinically.
Animal studies can show impressive lifespan extension. Human trials generally begin by asking more practical questions:
- Does the drug appear safe?
- Does it improve physical function?
- Does it improve immune function?
- Does it reduce frailty?
- Does it improve metabolic health?
- Does it delay one or more age-related diseases?
- Does it improve validated measures of healthspan?
- Ultimately, does it reduce disability or mortality?
Only after these questions are answered can we begin to estimate whether a drug meaningfully extends human healthspan or lifespan.
Anti-Aging Drugs vs. Lifestyle: Where Does the Evidence Stand?
At present, the evidence hierarchy looks something like this:
- Lifestyle fundamentals: strong evidence for reducing premature mortality and major chronic disease risk.
- Prescription treatment of established risk factors: strong evidence when appropriately indicated—for example, treating hypertension, diabetes or dyslipidemia.
- Geroscience drugs such as rapamycin and metformin: biologically compelling and increasingly supported by human trials, but not proven to extend lifespan in healthy humans.
- Senolytics and other emerging gerotherapeutics: promising but still experimental.
- Longevity supplements: evidence varies widely, with limited evidence that any specific supplement extends human lifespan.
- Animal-only longevity interventions: useful for hypothesis generation but not evidence of human lifespan extension.
This means that, in 2026, lifestyle remains the safest and best-supported longevity intervention for the general population.
The exciting possibility is that future therapies may eventually complement—not replace—those fundamentals.
The emerging longevity model is therefore not “drug instead of lifestyle.”
It is potentially healthy lifestyle + precision prevention + effective treatment of risk factors + carefully validated geroscience therapies.
The final component remains experimental—but it could become one of the most important developments in medicine if clinical trials demonstrate meaningful improvements in human healthspan.
There Is Another Category We Shouldn't Overlook: Drugs That Prevent Age-Related Disease
There is an important category of medicines that can be overlooked in discussions about longevity: drugs that prevent or delay age-related disease.
In practical terms, this may ultimately be more important than the pursuit of a single "anti-aging drug."
Many of the diseases that shorten human life are strongly influenced by modifiable cardiovascular, metabolic and renal risk factors. When an effective medication substantially reduces the risk of one of these diseases, it can potentially increase health-adjusted life expectancy even if it has no effect on the fundamental biological mechanisms of aging.
GLP-1 Receptor Agonists
GLP-1 receptor agonists such as semaglutide have transformed the treatment of obesity and type 2 diabetes.
Beyond weight loss and glucose control, large randomized trials have demonstrated cardiovascular benefits in selected patient populations. For example, the SELECT trial found that semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease who did not have diabetes.
SELECT trial, New England Journal of Medicine (2023)
These findings are highly relevant to longevity because cardiovascular disease is one of the world's major causes of death.
However, it would be premature to conclude that semaglutide or other GLP-1 drugs are "anti-aging drugs."
SGLT2 Inhibitors
SGLT2 inhibitors provide another important example.
Originally developed as glucose-lowering drugs for type 2 diabetes, medications such as empagliflozin and dapagliflozin have demonstrated important cardiovascular and kidney benefits in appropriately selected patients, including people with heart failure and chronic kidney disease.
For example, the EMPA-REG OUTCOME trial demonstrated a reduction in cardiovascular death and hospitalization for heart failure with empagliflozin in people with type 2 diabetes and established cardiovascular disease.
EMPA-REG OUTCOME, New England Journal of Medicine (2015)
Subsequent trials have expanded the evidence for SGLT2 inhibitors across heart failure and chronic kidney disease populations.
DAPA-CKD, New England Journal of Medicine (2020)
Again, the longevity implication is indirect: preventing cardiovascular and renal events can help people live longer and healthier lives, but this does not establish that SGLT2 inhibitors slow biological aging itself.
The Same Principle Applies to Other Preventive Medicines
The distinction extends well beyond GLP-1 receptor agonists and SGLT2 inhibitors.
Several established drug classes can reduce the risk of major diseases that become increasingly common with age:
- Statins — lower LDL cholesterol and reduce the risk of major cardiovascular events in appropriately selected patients.
- Antihypertensive drugs — reduce complications associated with high blood pressure, including stroke, heart failure and cardiovascular disease.
- Aspirin in selected populations — can reduce certain cardiovascular events in specific high-risk groups, although routine primary-prevention use is not appropriate for everyone because bleeding risk can outweigh potential benefit.
- Diabetes medications — can reduce complications of diabetes, with some newer classes providing cardiovascular and/or kidney benefits beyond glucose lowering.
- Osteoporosis medications — can reduce fractures, which are an important cause of disability, loss of independence and excess mortality in older adults.
These interventions may therefore contribute to longer health-adjusted life expectancy by preventing specific causes of illness, disability and death.
But Preventing Disease Is Not the Same as Slowing Aging
This distinction is fundamental to understanding modern longevity medicine.
Consider two hypothetical interventions.
Intervention A slows a fundamental biological aging process and consequently reduces the risk of many age-related diseases simultaneously.
Intervention B substantially reduces the probability of dying from one particular disease, such as cardiovascular disease, but does not alter the underlying rate of biological aging.
Both could potentially increase lifespan.
But only Intervention A would properly qualify as a treatment designed to modify the aging process itself.
In reality, the boundary may eventually become less clear. Some conventional drugs may influence multiple biological pathways associated with aging, while some geroscience interventions may prevent specific diseases. Clinical outcomes—not marketing terminology—will ultimately determine where a drug belongs.
Three Different Longevity Concepts
1. Disease prevention
Reduce the probability of developing or dying from a specific disease.
2. Healthspan extension
Increase the number of years a person remains physically and cognitively healthy.
3. Biological aging modification
Alter fundamental aging processes in a way that delays multiple age-related diseases and potentially extends healthy lifespan.
A medication can accomplish the first without necessarily accomplishing the third.
Why This Matters for Longevity
From the patient's perspective, the distinction may seem academic.
If a medication prevents a heart attack, stroke, kidney failure or debilitating fracture, the result may be more years of life and more years of functional health.
But scientifically, it is important not to confuse this outcome with evidence that the drug slows aging.
This is particularly relevant as newer drugs such as GLP-1 receptor agonists generate enormous interest in longevity research.
The correct question is not simply:
"Does this drug make people live longer?"
Instead, researchers need to ask:
- Does it reduce all-cause mortality?
- Does it reduce major age-related diseases?
- Does it delay disability?
- Does it increase disease-free life expectancy?
- Does it improve physical and cognitive function?
- Does it modify validated markers or mechanisms of biological aging?
- Does it provide benefits beyond those expected from preventing a particular disease?
These questions help distinguish risk-factor treatment from genuine geroscience.
So, Are GLP-1 Drugs and SGLT2 Inhibitors Longevity Drugs?
Potentially relevant to longevity, yes. Proven anti-aging drugs, no.
GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated important clinical benefits in appropriately selected patients. Those benefits can plausibly translate into longer and healthier lives by preventing serious disease.
But we do not currently have sufficient evidence to say that drugs such as Ozempic or Wegovy, or SGLT2 inhibitors such as empagliflozin and dapagliflozin, slow the fundamental biological aging process.
The same principle applies to statins, antihypertensive drugs, selected use of aspirin, diabetes medications and osteoporosis treatments.
They may extend life by preventing specific causes of disease and death without necessarily changing the underlying biological rate of aging.
That is not a limitation of these medicines. Quite the opposite: preventing disease is one of the most powerful and evidence-based ways modern medicine already extends healthy human life.
Why You Should Be Careful With “Years Added to Life” Claims
Most lifestyle-longevity research is observational.
Researchers observe what people do and then compare mortality between groups. This can reveal remarkably consistent associations, but it cannot completely eliminate confounding.
For example, people who exercise regularly may also:
- Have higher incomes
- Have better access to healthcare
- Smoke less
- Eat healthier diets
- Sleep differently
- Have different occupational exposures
- Have different social networks
Researchers statistically adjust for many of these factors, but statistical adjustment cannot guarantee that all confounding has been removed.
There is another issue: reverse causation.
People developing serious illness may become less active or lose weight. If researchers then observe that inactivity or low body weight is associated with higher mortality, some of the association may reflect pre-existing disease rather than the behavior itself causing death.
Evidence Hierarchy: How Strong Is the Longevity Evidence?
Tier 1 — Randomized controlled trials
Best for determining whether an intervention causes a specific outcome. However, decades-long randomized trials measuring lifespan are rare and difficult to conduct.
Tier 2 — Systematic reviews and meta-analyses of high-quality trials
Especially useful when multiple randomized trials exist. They can provide stronger estimates of effects on cardiovascular events, diabetes, cancer and other outcomes.
Tier 3 — Large prospective cohort studies
Extremely valuable for studying long-term mortality and lifestyle because lifespan cannot easily be studied in short randomized trials. However, associations do not prove causation.
Tier 4 — Life-table and statistical modelling
Useful for translating observed mortality differences into estimated life expectancy. These are projections, not direct measurements of how many years an individual will live.
Tier 5 — Mechanistic, laboratory and animal research
Useful for understanding biological plausibility and generating hypotheses, but it cannot establish that an intervention extends human lifespan.
Tier 6 — Testimonials, anecdotes and marketing claims
These can generate hypotheses but provide very weak evidence for estimating longevity benefits.
So, How Many Years Can a Healthy Lifestyle Really Buy?
The most defensible answer is a range rather than a single number.
Large observational studies suggest that the difference between a very unhealthy lifestyle and a consistently healthy lifestyle can be measured in several years and, in some populations and modelling approaches, more than a decade.
The landmark Harvard analysis estimated approximately 12–14 additional years of projected life expectancy at age 50 when comparing five low-risk lifestyle factors with none.
Other cohorts have produced smaller estimates, while studies examining disease-free or disability-free years have sometimes found similarly large differences in healthy life expectancy.
This variation is not a contradiction. Different studies use different populations, lifestyle definitions, follow-up periods, statistical methods and comparison groups.
The most scientifically honest takeaway:
Healthy living probably does not “buy” a fixed number of years. Instead, it shifts the odds—often substantially—toward longer survival and more years free from major chronic disease.
Healthspan May Matter More Than Lifespan
Living to 95 is not necessarily a better outcome if the final 15 years are dominated by severe disability, cardiovascular disease, dementia or multiple chronic illnesses.
For this reason, researchers increasingly distinguish between:
- Lifespan: how long you live.
- Healthspan: how long you remain relatively healthy and functional.
- Disease-free life expectancy: how long you live without specified major diseases.
- Disability-free life expectancy: how long you live without significant functional disability.
The BMJ study discussed above is particularly interesting because it found that healthy lifestyle behaviors were associated not simply with longer life, but with more years free from cancer, cardiovascular disease and type 2 diabetes.
The Biggest Longevity “Return on Investment”
If the objective is maximizing healthy years rather than collecting supplements, the evidence suggests prioritizing the fundamentals.
- Do not smoke.
- Exercise regularly. Aim for at least 150–300 minutes of moderate activity weekly, plus strength training.
- Eat a predominantly minimally processed, plant-forward diet.
- Maintain a healthy metabolic profile and body composition.
- Keep blood pressure, glucose and lipids under control.
- Sleep adequately and consistently.
- Maintain meaningful social relationships and cognitive activity.
- Limit alcohol rather than treating it as medicine.
- Use supplements selectively when there is a plausible indication or deficiency.
- Use preventive healthcare and evidence-based screening appropriate to age and risk.
These interventions may look ordinary. That is precisely the point.
The strongest evidence for longevity does not currently come from a single molecule or “anti-aging stack.” It comes from reducing the major causes of premature disease and death.
What About Genetics?
Genetics clearly influences lifespan and disease risk, but genetic predisposition does not make lifestyle irrelevant.
Large studies increasingly suggest that lifestyle and inherited risk interact. A person cannot choose their genes, but many major modifiable risk factors remain actionable regardless of genetic background.
This is another reason to think in terms of risk reduction rather than guaranteed lifespan extension.
What About Starting Late?
It is never necessary to assume that healthy living only matters if started in youth.
Observational evidence indicates that healthier behaviors remain associated with better outcomes even when adopted in middle and older age.
The exact magnitude of benefit depends on the person's starting point. Someone who quits smoking, becomes physically active and improves metabolic health may have much more potential benefit than someone who already follows most healthy behaviors.
The important principle is therefore:
Do not let the absence of a perfect lifestyle become an excuse for doing nothing.
What We Still Do Not Know
Despite impressive epidemiological evidence, several important questions remain unresolved.
- How much can lifestyle extend maximum human lifespan?
- Which interventions slow biological aging itself?
- How much of the benefit comes from cardiovascular prevention versus other mechanisms?
- Can specific supplements meaningfully extend human lifespan?
- Can combinations of lifestyle interventions produce benefits beyond their individual effects?
- What is the optimal amount of exercise for different ages and health conditions?
- Can personalized interventions based on genetics, biomarkers and biological age substantially improve outcomes?
These questions are active areas of research. Claims that science has already answered them with precision should be treated skeptically.
Frequently Asked Questions
Can a healthy lifestyle add 10 years to your life?
It can potentially make a difference of that magnitude at the population level. A major Harvard analysis estimated approximately 12 additional years for men and 14 for women at age 50 when comparing people with five low-risk lifestyle factors against those with none. However, this was an observational study combined with life-table modelling, so it should not be interpreted as a guaranteed individual benefit.
What lifestyle change has the biggest effect on lifespan?
There is no universal ranking for every individual. Smoking cessation is particularly powerful for smokers, while physical activity, healthy diet, healthy body composition and control of cardiovascular risk factors each contribute to lower disease and mortality risk.
Does exercise really extend life?
Regular physical activity is consistently associated with lower mortality and cardiovascular risk. WHO recommends at least 150–300 minutes of moderate aerobic activity or 75–150 minutes of vigorous activity per week, plus muscle-strengthening activity on at least two days per week.
Can supplements extend lifespan?
There is currently no strong human evidence showing that a supplement reliably adds a specific number of years to lifespan in healthy adults. Supplements can be valuable for correcting deficiencies or addressing specific medical or nutritional needs, but they should not be considered equivalent to the evidence for basic lifestyle interventions.
Is a multivitamin proven to make you live longer?
No. The USPSTF concluded that evidence was insufficient to determine whether multivitamins prevent cardiovascular disease or cancer. Some trials have suggested modest benefits for particular outcomes, but this is not equivalent to proving a meaningful increase in lifespan.
Should I take vitamin D for longevity?
Vitamin D is important for health, particularly when a person is deficient, but randomized evidence has not established that routine vitamin D supplementation extends lifespan in generally healthy adults. Supplementation should therefore be based on nutritional needs and clinical context rather than an assumption that it is an anti-aging drug.
Is the Mediterranean diet a longevity diet?
Mediterranean-style dietary patterns are strongly associated with cardiovascular and metabolic benefits and have been studied extensively. It is more accurate to describe the pattern as a well-supported healthy dietary approach than to claim that it has a guaranteed lifespan-extending effect.
Can you undo years of unhealthy living?
Some risks can fall substantially after behavior changes, particularly after smoking cessation and improvements in physical activity and metabolic health. However, previous exposures can leave lasting effects. It is better to think in terms of reducing future risk than completely erasing the past.
Is healthspan more important than lifespan?
For many people, yes. The goal of preventive medicine is not simply to postpone death but to increase the number of years lived with good physical, cognitive and functional health.
Bottom Line
The evidence does not support a precise formula such as “healthy diet = 5 years, exercise = 4 years, supplements = 2 years.” Human longevity is too complex for that.
But the overall evidence is remarkably consistent.
Not smoking, being physically active, eating a high-quality diet, maintaining healthy metabolic function and avoiding major preventable risk factors can substantially improve the probability of living longer—and potentially living more years in good health.
The strongest studies suggest that the difference between a very unhealthy and very healthy lifestyle can reach roughly a decade or more of projected life expectancy in some populations.
Supplements may have a role, particularly when they correct deficiencies or address specific needs, but they currently sit much lower in the evidence hierarchy for lifespan extension than the fundamentals of preventive health.
Don't smoke + move regularly + eat mostly minimally processed foods + maintain healthy metabolic function + preserve muscle and fitness + sleep adequately + use preventive healthcare + correct genuine nutritional deficiencies.
Medical disclaimer: This article is an educational review of population-level evidence and is not individual medical advice. Life-expectancy estimates from observational studies and modelling should not be interpreted as predictions for any particular person. Individual recommendations should take into account age, medical history, medications, nutritional status, physical ability and personal risk factors.
Selected Evidence & References
- Li Y, Pan A, Wang DD, et al. Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population. Circulation. 2018;138:345–355. PubMed
- Li Y, Pan A, Wang DD, et al. Full article. PMC / Circulation
- Nyberg ST, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. BMJ. 2020. BMJ
- Larsson SC, Kaluza J, Wolk A. Combined impact of healthy lifestyle factors on lifespan: two prospective cohort studies. Journal of Internal Medicine. 2017. PubMed
- World Health Organization. Physical activity. WHO
- U.S. Preventive Services Task Force. Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer. 2022. USPSTF
- O'Connor EA, Evans CV, Ivlev I, et al. Vitamin and Mineral Supplementation to Prevent Cardiovascular Disease and Cancer: Systematic Review. USPSTF Evidence Summary
- I-PREVENT Aging Protocol: Anti Aging Guide to Help People Prevent and Reverse Aging. 2026. OneDayMD
.png)
Comments